PremiumCompany AnnouncementsAgios Pharmaceuticals Reports Q1 2025 Progress and Outlook Agios Pharmaceuticals’ Earnings Call: Optimism Amid Challenges Agios Pharma’s Strategic Advances and Mitapivat’s Market Potential Drive Buy Rating PremiumThe FlyAlibaba upgraded, Rivian downgraded: Wall Street’s top analyst calls Agios Pharmaceuticals initiated with a Buy at H.C. Wainwright Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank PremiumThe FlyAgios Pharmaceuticals reports results from Phase 3 ACTIVATE-Kids study Agios Pharma Board Member Announces Resignation Agios Pharmaceuticals price target lowered to $54 from $55 at BofA 
